T. Rowe Price Associates’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$154M Sell
508,464
-34,169
-6% -$10.3M 0.02% 486
2025
Q1
$180M Sell
542,633
-46,131
-8% -$15.3M 0.02% 448
2024
Q4
$182M Sell
588,764
-144,933
-20% -$44.7M 0.02% 450
2024
Q3
$156M Sell
733,697
-125,068
-15% -$26.5M 0.02% 484
2024
Q2
$241M Buy
858,765
+55,552
+7% +$15.6M 0.03% 386
2024
Q1
$214M Buy
803,213
+414,484
+107% +$111M 0.03% 411
2023
Q4
$89.9M Buy
388,729
+218,356
+128% +$50.5M 0.01% 568
2023
Q3
$24.9M Buy
170,373
+114,970
+208% +$16.8M ﹤0.01% 866
2023
Q2
$12.8M Buy
55,403
+8,403
+18% +$1.94M ﹤0.01% 1030
2023
Q1
$11.4M Sell
47,000
-8,250
-15% -$2M ﹤0.01% 1035
2022
Q4
$16M Buy
55,250
+8,629
+19% +$2.5M ﹤0.01% 968
2022
Q3
$3.03M Buy
46,621
+4,219
+10% +$274K ﹤0.01% 1298
2022
Q2
$3.04M Sell
42,402
-2,497
-6% -$179K ﹤0.01% 1500
2022
Q1
$4.41M Sell
44,899
-3,554
-7% -$349K ﹤0.01% 1484
2021
Q4
$4.11M Sell
48,453
-9,347
-16% -$792K ﹤0.01% 1525
2021
Q3
$4.61M Sell
57,800
-18,455
-24% -$1.47M ﹤0.01% 1518
2021
Q2
$7.43M Sell
76,255
-9,286
-11% -$905K ﹤0.01% 1451
2021
Q1
$10M Sell
85,541
-85,668
-50% -$10M ﹤0.01% 1394
2020
Q4
$19M Sell
171,209
-4,436
-3% -$493K ﹤0.01% 1234
2020
Q3
$20.9M Buy
175,645
+31,670
+22% +$3.76M ﹤0.01% 1147
2020
Q2
$16.3M Buy
143,975
+97,257
+208% +$11M ﹤0.01% 1190
2020
Q1
$3.12M Sell
46,718
-701
-1% -$46.8K ﹤0.01% 1407
2019
Q4
$4.32M Sell
47,419
-95,114
-67% -$8.67M ﹤0.01% 1421
2019
Q3
$12.3M Sell
142,533
-88,337
-38% -$7.62M ﹤0.01% 1255
2019
Q2
$24.2M Sell
230,870
-30,667
-12% -$3.21M ﹤0.01% 1122
2019
Q1
$32.8M Buy
261,537
+518
+0.2% +$64.9K ﹤0.01% 1020
2018
Q4
$29.4M Sell
261,019
-239,858
-48% -$27M 0.01% 1011
2018
Q3
$107M Sell
500,877
-67,251
-12% -$14.4M 0.02% 651
2018
Q2
$159M Buy
568,128
+382,109
+205% +$107M 0.02% 531
2018
Q1
$21.7M Buy
+186,019
New +$21.7M ﹤0.01% 1153